Physician profile
Mark B Deyoung
NPI 1306845045
$585.19
in general payments reported to CMS, 2019-2025
12 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.28 · 2020: $17.55 · 2021: $187 · 2022: $66.66 · 2023: $66.66 · 2024: $75.52 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $269.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $160.44 | 2021-2023 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $99.60 | 2023-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $87.16 | 2021-2025 | Freestyle Libre 3 |
| Insulet Corporation | $45.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.56 | 2021-2023 | Xifaxan, Trulance |
| Pfizer INC. | $36.36 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $32.87 | 2021 | |
| Zimmer Biomet Holdings, INC. | $19.82 | 2025 | Persona |
| Medtronic, INC. | $19.70 | 2025 | Inceptiv |
| Novo Nordisk INC | $17.55 | 2020 | |
| Lilly USA, LLC | $14.36 | 2022 | |
| Astellas Pharma US INC | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Deyoung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.